These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35115900)

  • 1. Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by
    Jung KH; Lee JH; Kim M; Lee EJ; Cho YS; Lee KH
    Mol Imaging; 2022; 2022():4906934. PubMed ID: 35115900
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Jung KH; Lee JH; Kim M; Cho YS; Lee KH
    Mol Imaging; 2022; 2022():5916692. PubMed ID: 35250391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET imaging of colon cancer CD73 expression using cysteine site-specific
    Jung KH; Kim M; Jung HJ; Koo HJ; Kim JL; Lee H; Lee KH
    Sci Rep; 2024 Aug; 14(1):17994. PubMed ID: 39097625
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Jung KH; Park JW; Lee JH; Moon SH; Cho YS; Lee KH
    J Nucl Med; 2021 May; 62(5):656-664. PubMed ID: 32917780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteine-specific
    Lee JH; Jung KH; Kim M; Lee KH
    Front Immunol; 2022; 13():1017132. PubMed ID: 36591250
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Park JW; Jung KH; Lee JH; Moon SH; Cho YS; Lee KH
    Sci Rep; 2021 Feb; 11(1):3876. PubMed ID: 33594192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
    Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
    J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Wyszatko K; Janzen N; Silva LR; Kwon L; Komal T; Ventura M; Venugopal C; Singh SK; Valliant JF; Sadeghi S
    EJNMMI Res; 2024 Mar; 14(1):29. PubMed ID: 38498285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Light-Induced Radiosynthesis of
    Klingler S; Fay R; Holland JP
    J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
    J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging Very Late Antigen-4 on MOLT4 Leukemia Tumors with Cysteine Site-Specific
    Kim M; Jung KH; Kim JL; Koo HJ; Jung HJ; Lee H; Lee KH
    Mol Pharm; 2024 Mar; 21(3):1353-1363. PubMed ID: 38282332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Broer LN; Knapen DG; Suurs FV; Moen I; Giesen D; Waaijer SJH; Indrevoll B; Ellingsen C; Kristian A; Cuthbertson AS; de Groot DA; Cole PE; de Vries EGE; Hagemann UB; Lub-de Hooge MN
    J Nucl Med; 2022 Nov; 63(11):1715-1721. PubMed ID: 35422447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [
    Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by
    Chomet M; Schreurs M; Nguyen M; Howng B; Villanueva R; Krimm M; Vasiljeva O; van Dongen GAMS; Vugts DJ
    Theranostics; 2020; 10(13):5815-5828. PubMed ID: 32483421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
    Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
    J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells.
    Deng Y; Su Q; Mo J; Fu X; Zhang Y; Lin EH
    Cancer Invest; 2013 Feb; 31(2):97-102. PubMed ID: 23245395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
    Glumac PM; Gallant JP; Shapovalova M; Li Y; Murugan P; Gupta S; Coleman IM; Nelson PS; Dehm SM; LeBeau AM
    Clin Cancer Res; 2020 Mar; 26(5):1054-1064. PubMed ID: 31732520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.